Over 3,000 Units of HFNC Delivered to Poland and Peru, Micomme Medical Helps the World Fight Against COVID-19 Pandemic
PR91042
CHANGSHA, China, Aug. 5, 2021/PRNewswire=KYODO JBN/--
Recently, Micomme has associated with Polish and Peruvian partners to
accomplish the government centralized purchase of 1,600 and 1,500 units of HFNC
respectively. Both purchases are strategic material reserves of the local
governments. The global pandemic is still ongoing, and the safety of people's
lives is the primary goal pursued by governments. The projects also reflect the
foresight and determination of the local governments. Both purchases were
delivered in June 2021.
As the leading non-invasive respiratory therapy company in China, Micomme
Medical launched their first transnasal High-Flow Nasal Cannula Oxygen Therapy
Device (hereinafter referred to as HFNC) OH-70C in 2017. At the beginning of
the pandemic outbreak, Micomme Medical responded quickly during the traditional
Chinese Spring Festival. All employees returned to work from holiday, the
production line was fully activated, and more than 5,000 units of HFNC were
sent to Wuhan immediately. In 2020, Micomme achieved more than 10,000 HFNC
installations worldwide (China not included), and helped countries around the
world fight against COVID-19 with a production capacity of 500 units per day.
The transnasal High-Flow Nasal Cannula Oxygen Therapy Device is the machine
recommended by WHO and related international guidelines for the treatment of
patients with COVID-19. It aims to quickly increase the patient's oxygen
saturation (SpO2) and improve the symptoms of hypoxia in patients by providing
a high-flow air-oxygen mixed gas to patients with a constant temperature,
humidity and a constant oxygen concentration. As one of the first HFNC
manufacture in China, Micomme has won the market's recognition with its
excellent product quality and brilliant product performance. In the battle
against COVID-19, Micomme fulfills the commitment as the leading company.
For more details, please contact: market.intl@micomme.com
Reference:
www.who.int/publications/i/item/clinical-care-of-severe-acute-respiratory-infections-tool-kit
Source: Micomme
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。